Investigational blood biomarker panel may improve detection of pancreatic cancer
A Penn Medicine study shows that a biomarker blood panel that incorporates four different proteins enhances the detection of pancreatic cancer compared to measuring CA19-9 levels alone.
2 min. read
A biomarker blood panel that incorporates four different proteins—ANPEP, PIGR, CA19-9, and THBS2—enhances the detection of pancreatic ductal adenocarcinoma (PDAC) compared to measuring CA19-9 levels alone, according to a study led by researchers from the Perelman School of Medicine. The study is published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Image: Sebastian Kaulitzk/Science Photo Library via Getty Images
PDAC, which forms from the exocrine cells in the pancreas, is the most common form of pancreatic cancer, accounting for about 95% of cases. When detected at a localized, early stage, the five-year relative survival is about 44%, but once the disease has metastasized, the five-year survival drops to 3%. Most cases of pancreatic cancer are diagnosed at late stages.
“Pancreatic cancer usually doesn't present with symptoms until it's too late for surgery, when the cancer has already metastasized to other parts of the body,” says Kenneth S. Zaret, senior author of the study and a professor of cell and developmental biology. “Our goal was to look for biomarkers in the blood that appear in early-stage PDAC patients, to catch the disease early,” he says.
CA19-9 is a protein that is released into the blood by both cancer cells and normal pancreatic cells, and elevated levels of CA19-9 in the blood can be a sign of pancreatic cancer or other diseases. THBS2 (thrombospondin 2) is a protein that is expressed in PDAC tumor tissue, and when screened for in blood alongside CA19-9 using a bioassay, enables the test to better discriminate between PDAC and healthy patients, according to previous work from Zaret and colleagues. However, Zaret notes that these biomarkers are insufficient for routine early detection.
“CA19-9 is widely used to monitor diagnosed pancreatic cancer but isn’t recommended as a standalone screening test—benign conditions can elevate it in some people, while others may have low levels, even if they have pancreatic cancer. THBS2 is investigational and can complement CA19-9, but its prediagnostic performance has been mixed,” Zaret says.
Novel plant-based approach to a better, cheaper GLP-1 delivery system
Research led by Penn Dental’s Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as a new oral delivery of two GLP-1 drugs previously approved by the FDA in injectable form.
No brain, no gain: Neuronal activity enhances benefits of exercise
Research led by Penn neuroscientist J. Nicholas Betley and collaborators finds that hypothalamic neurons are essential for translating physical exertion into endurance, potentially opening the door to exercise-mimicking therapies.
In honor of Valentine's Day, and as a way of fostering community in her Shakespeare in Love course, Becky Friedman took her students to the University Club for lunch one class period. They talked about the movie "Shakespeare in Love," as part of a broader conversation on how Shakespeare's works are adapted.
In Becky Friedman’s English course Shakespeare in Love, undergraduate students analyze language, genre, and adaptation in the Bard’s plays through the lens of love.
Beating the heat: Designing cooling for bodies in motion
Dorit Aviv, director of Weitzman’s Thermal Architecture Lab, studies how humans, technology, and design intersect, paving the way for the development of novel approaches to cooling people efficiently.
